Maitland, Michael L.
Piha-Paul, Sarina
Falchook, Gerald
Kurzrock, Razelle
Nguyen, Ly
Janisch, Linda
Karovic, Sanja
McKee, Mark
Hoening, Elizabeth
Wong, Shekman
Munasinghe, Wijith
Palma, Joann
Donawho, Cherrie
Lian, Guinan K.
Ansell, Peter
Ratain, Mark J.
Hong, David
Article History
Received: 12 October 2017
Revised: 8 January 2018
Accepted: 15 January 2018
First Online: 19 March 2018
Competing interest
: M.M., E.H., S.W., W.M., J.P., C.D., and P.A.: AbbVie employees and may own stock and/or options. G.K.L.: Contractor statistician from inVentiv Health Inc. G.F.: Has research funding from AbbVie. R.K.: Has research funding from Genentech, Merck Serono, Pfizer, Sequenom, Foundation Medicine, and Guardant, as well as consultant/advisory board fees from Actuate Therapeutics and XBiotech, and an ownership interest in CureMatch, Inc. M.J.R.: Consultant to AbbVie. D.H.: Has research/grant funding from Bayer, Lilly, Genentech, Loxo, Pfizer, Amgen, Mirati, Ignyta, Merck, Daiichi Sankyo, Eisai; travel, accommodations, expenses from Mirna, Loxo; consulting or advisory role with Bayer, Baxter, Guidepoint Global; other ownership interests with OncoResponse (founder). The remaining authors declare no competing financial interests.